{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-068011","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2022-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.503233+00:00","generated_at":"2026-06-27T01:11:09.629398+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo appoints Michael P. Cruse as COO and Jennifer P. Lam as principal financial officer","bullets":["Michael P. Cruse appointed COO effective March 2, 2022; base salary increased to $400K (from $350K) and bonus target to 40%.","Cruse granted option for 25,000 shares vesting in 48 equal monthly installments; severance extended to 12 months post-change-of-control.","Jennifer P. Lam named principal financial and accounting officer effective March 31, 2022; base salary raised to $320K (from $309K).","Lam granted option for 10,000 shares vesting over 48 months; she previously served as VP of Finance & Administration since August 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-068011","json":"https://secwatch.observer/filing/0001193125-22-068011.json","markdown":"https://secwatch.observer/filing/0001193125-22-068011.md","text":"https://secwatch.observer/filing/0001193125-22-068011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/0001193125-22-068011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/d326180d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:11:09.629398+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6190787300","claim":"Jennifer P. Lam was appointed as principal financial and accounting officer at OnKure Therapeutics, Inc..","evidence_excerpt":"On March 2, 2022, the Board appointed Jennifer P. Lam, the Company’s Vice President of Finance & Administration, as the Company’s principal financial and accounting officer, effective March 31, 2022 (the “Lam Appointment”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/0001193125-22-068011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal financial and accounting officer"}],"fact_type":"executive_change"},{"claim_id":"955ddcc3b8","claim":"Michael P. Cruse was appointed as Chief Operating Officer at OnKure Therapeutics, Inc..","evidence_excerpt":"On March 2, 2022, the Board of Directors (the “Board”) of Reneo Pharmaceuticals, Inc. (the “Company”) appointed Michael P. Cruse as the Company’s Chief Operating Officer, effective immediately (the “Cruse Appointment”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312522068011/0001193125-22-068011-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}